《雅思阅读考试第一步》由会员分享，可在线阅读，更多相关《雅思阅读考试第一步（7页珍藏版）》请在金锄头文库上搜索。
1、雅思阅读考试第一步雅思阅读考试时间有限，时间紧，文章长，文意难懂句型复杂，如何才能化繁为简,今天小编给大家带来了雅思阅读考试第一步-确定做题顺序,希望能够帮忙到大家，下面小编就和大家分享，来观赏一下吧雅思阅读考试第一步-确定做题顺序一、首先决定要以什么样的顺序做题。真正的雅思考试并不是想象中的由易到难，很有可能一开始的文章就很难。构想，如果用30分钟先解决一道难题，再用剩下的30分钟去完成两道简单的题目，效果注定不好!试举剑桥4中TEST2 为例，三篇文章分别 “lost for words, “alternative medicine in Australia, “play is aseri
2、ous business.乍一看第三篇文章题目是最简单的，实际上它反而是最难的。二、题型决定做题顺序，而不是题目。“lost for words题型分别是：summary, 人名理论matching, yes/no/notgiven. “alternative medicine in Australia题型分别是：multiple choices, yes/no/notgiven, 填空题. “play is a seriousbusiness题型分别是：信息段落配对，多项选择多，人名理论配对。初步分析题型后还可以细化，理清做题思路。第一篇文章难度适中，summary属主旨类型题倡议先做，同时
3、可以把人名全部找到以节省时间。matching题中出现五对五配对还有NB。第二篇文章题目虽难但是引言局部交待很分明，属简单的题目。填空题实属数字游戏，整篇文章完全按顺序出题。第三篇文章难度系数较大，信息段落配对难把握，之后的人名理论配对干扰选项过多，从一开始相当于八选一。这样分析下来，我们的做题顺序应该是“Passage2/1/3。三、掌握技巧，灵活运用。题型没有绝对的难易之分，对其他考生难也许对你反而容易，要结合自己的实际情况。可以先做送分题“表格填空，图形题，完成句子。在五大主流题型中，配对题比拟费时，其中信息和段落配对最花时间，倡议放在最后。而作为主旨的heading和summary 可
4、考虑先做，因为完成主旨题型后文章大致的内容和结构都可以掌握，对于细节题的定位会方便很多。雅思考试像是一场战斗，应该灵活运用作战的策略和办法，后期更需要成套的阅读训练。如果能够运用这些提高效率节省时间的办法，有助于学生信心的塑造和雅思分数的提高。雅思阅读模拟练习及答案1. The failure of a high-profile cholesterol drug has thrown a spotlight onthe complicated machinery that regulates cholesterol levels. But manyresearchers remain conf
5、ident that drugs to boost levels of good cholesterolare still one of the most promising means to combat spiralling heartdisease.2. Drug company Pfizer announced on 2 December that it was cancelling allclinical trials of torcetrapib， a drug designed to raise heart-protectivehigh-density lipoproteins
6、(HDLs)。 In a trial of 15000 patients， a safety boardfound that more people died or suffered cardiovascular problems after taking thedrug plus a cholesterol-lowering statin than those in a control group who tookthe statin alone.3. The news came as a kick in the teeth to many cardiologists because ear
7、liertests in animals and people suggested it would lower rates of cardiovasculardisease. “There have been no red flags to my knowledge， says John Chapman， aspecialist in lipoproteins and atherosclerosis at the National Institute forHealth and Medical Research (INSERM) in Paris who has also studied t
8、orcetrapib.“This cancellation came as a complete shock.4. Torcetrapib is one of the most advanced of a new breed of drugs designedto raise levels of HDLs， which ferry cholesterol out of artery-clogging plaquesto the liver for removal from the body. Specifically， torcetrapib blocks aprotein called ch
9、olesterol ester transfer protein (CETP)， which normallytransfers the cholesterol from high-density lipoproteins to low density，plaque-promoting ones. Statins， in contrast， mainly work by lowering the badlow-density lipoproteins.Under pressure5. Researchers are now trying to work out why and how the
10、drug backfired，something that will not become clear until the clinical details are released byPfizer. One hint lies in evidence from earlier trials that it slightly raisesblood pressure in some patients. It was thought that this mild problem would beoffset by the heart benefits of the drug. But it i
11、s possible that it actuallyproved fatal in some patients who already suffered high blood pressure. If bloodpressure is the explanation， it would actually be good news for drug developersbecause it suggests that the problems are specific to this compound. Otherprototype drugs that are being developed
12、 to block CETP work in a slightlydifferent way and might not suffer the same downfall.6. But it is also possible that the whole idea of blocking CETP is flawed，says Moti Kashyap， who directs atherosclerosis research at the VA Medical Centerin Long Beach， California. When HDLs excrete cholesterol in
13、the liver， theyactually rely on LDLs for part of this process. So inhibiting CETP， whichprevents the transfer of cholesterol from HDL to LDL， might actually cause anabnormal and irreversible accumulation of cholesterol in the body. “Youreblocking a physiologic mechanism to eliminate cholesterol and
14、effectivelyconstipating the pathway， says Kashyap.Going up7. Most researchers remain confident that elevating high density lipoproteinslevels by one means or another is one of the best routes for helping heartdisease patients. But HDLs are complex and not entirely understood. One approveddrug， calle
15、d niacin， is known to both raise HDL and reduce cardiovascular riskbut also causes an unpleasant sensation of heat and tingling. Researchers areexploring whether they can bypass this side effect and whether niacin can lowerdisease risk more than statins alone. Scientists are also working on severalo
16、ther means to bump up high-density lipoproteins by， for example， introducingsynthetic HDLs. “The only thing we know is dead in the water is torcetrapib， notthe whole idea of raising HDL， says Michael Miller， director of preventivecardiology at the University of Maryland Medical Center， Baltimore.Questions 1-7This passage has 7 para
